Neuren’s Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome MELBOURNE, Australia, March 24, 2017 (GLOBE NEWSWIRE) -- Neuren Pharmaceuticals (NEU.AX) has reported top-line results for its Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. ...